Conventional Treatment and Medication Safety
At a Glance
Recurrent pericarditis is usually treated with an anti-inflammatory medicine plus colchicine, followed by a slow, clinician-guided taper once chest pain is gone and inflammation tests are normal. Steroids require extra caution because they can increase recurrence and serious side effects.
Treating a recurrence of pericarditis requires a shift in strategy. Unlike a first episode, which might resolve quickly, a recurrence often requires a longer, more structured approach to medication to calm your immune system and prevent the next flare [1]. All prescribed drugs, doses, durations, and monitoring must be individualized by your clinician.
The First-Line Defense: NSAIDs and Colchicine
The standard treatment for a flare involves a combination of two medications: a high-dose Non-Steroidal Anti-Inflammatory Drug (NSAID) (such as aspirin, ibuprofen, or indomethacin) and colchicine [2][1].
- The Goal of NSAIDs: These are used at “anti-inflammatory doses,” which are higher than what you might take for a headache. They work to quickly extinguish the active inflammation [1]. Safety Warning: High-dose NSAIDs carry serious risks of stomach ulcers, gastrointestinal bleeding, kidney injury, and dangerous interactions with anticoagulants. Call your doctor immediately for black/tarry stools or reduced urine output. You must inform your doctor if you have kidney disease, heart failure, uncontrolled hypertension, or are pregnant. Your doctor may prescribe a medication for gastroprotection.
- The Goal of Colchicine: Colchicine is the cornerstone of preventing future recurrences. In clinical trials, adding colchicine reduced the risk of another flare by about 50% [3][4]. For a recurrence, guidelines recommend continuing colchicine for at least 6 months [5][1]. Safety Warning: Colchicine requires precise dose adjustments for kidney or liver impairment and has severe interactions with many other medications (via the CYP3A4 pathway). Contact your clinician urgently if you experience severe diarrhea, vomiting, muscle weakness, or numbness. Never stop or double a dose without instruction.
The Importance of the Taper
One of the most common reasons for a “rebound” flare is stopping medication too quickly. Tapering schedules vary widely, but tapering should generally only begin once two conditions are met:
- You are symptom-free: You have no chest pain [1].
- CRP is normal: Your blood tests (C-Reactive Protein) show that the systemic inflammation has resolved [1][6].
Once these markers are stable, your doctor will slowly reduce your NSAID dose over several weeks. Tapering must be highly individualized, but tapering too rapidly has been linked to a higher risk of the inflammation returning [7].
Second-Line Treatment: The ‘Steroid Trap’
Corticosteroids (like prednisone) are considered second-line treatments. They are typically reserved for patients who cannot take NSAIDs (due to kidney issues or blood thinners), pregnant patients, or those whose symptoms do not respond to the first-line combination [8][9].
While steroids are very effective at stopping pain quickly, they come with a significant warning known as the “steroid trap”:
- Increased Recurrence Risk: Some evidence suggests that using steroids—especially at high doses—can make you more likely to have future flares [10][11].
- Steroid Dependence: Approximately 28% of patients with recurrent pericarditis become “steroid-dependent,” meaning their symptoms return every time they try to lower the dose below a certain point [12].
- Long-Term Side Effects: Prolonged use requires monitoring for serious health issues, including bone thinning (osteoporosis), high blood sugar (hyperglycemia), eye health, and increased infection risk [12][13].
- DANGER: Never Stop Abruptly: You must never stop taking prednisone abruptly due to the risk of life-threatening adrenal suppression, even if the pain is better. Tapering must be strictly supervised by your doctor. Notify your doctor if you become seriously ill or require surgery while on steroids [14][11].
To avoid this trap, current guidelines recommend using low-to-moderate doses (0.2 to 0.5 mg/kg/day) and an exceptionally slow, supervised tapering schedule [14][11].
Rest as Part of the Care Plan
During an active flare, your heart needs rest. However, this does not mean mandatory bed rest unless instructed. Activity restrictions should be individualized:
- Active Phase: Strenuous activities and competitive sports should be avoided to prevent worsening the inflammation [15]. You should stick to light activities.
- Recovery Phase: You can typically begin a clinician-approved, graded return to exercise only after your symptoms have completely resolved and your inflammatory markers have normalized [16][15]. Your doctor may use imaging or blood tests (like troponin, for myocardial involvement) to confirm it is safe to resume more intense physical activity.
Common questions in this guide
What is the usual first treatment for a recurrent pericarditis flare?
How is my colchicine dose chosen?
When is it safe to taper medicine for recurrent pericarditis?
Why are steroids used cautiously for recurrent pericarditis?
Can I stop prednisone when my pericarditis pain improves?
What medication side effects need urgent attention?
When can I exercise after a recurrent pericarditis flare?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Idiopathic recurrent pericarditis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my weight and kidney function, what is the correct daily dose of colchicine for me?
- 2.How slowly should we taper my NSAID once my CRP levels have normalized?
- 3.If we have to use prednisone, can we keep the dose at or below 0.5 mg/kg per day to reduce the risk of future flares?
- 4.What is our specific plan for tapering my medications if my symptoms return during the process?
- 5.What specific 'low-intensity' activities are safe for me to do while we wait for my inflammatory markers to stabilize?
References
References (16)
- 1
Diagnosis, Risk Stratification, and Treatment of Pericarditis: A Review.
Cremer PC, Klein AL, Imazio M
JAMA 2024; (332(13)):1090-1100 doi:10.1001/jama.2024.12935.
PMID: 39235771 - 2
Comparison of Colchicine Monotherapy Versus Nonsteroidal Anti-Inflammatory Drugs Monotherapy or Combination Therapy for the Prevention of Recurrent Pericarditis in Patients With Heart Failure With Reduced Ejection Fraction and/or Coronary Artery Disease.
Musick K, Knoell C, Clarke MM
Journal of pharmacy practice 2024; (37(4)):900-905 doi:10.1177/08971900231196081.
PMID: 37656800 - 3
Pharmacologic treatment of acute and recurrent pericarditis: a systematic review and meta-analysis of controlled clinical trials.
Avondo S, Andreis A, Casula M, et al.
Panminerva medica 2021; (63(3)):314-323 doi:10.23736/S0031-0808.21.04263-4.
PMID: 34738773 - 4
Recurrent pericarditis: new and emerging therapeutic options.
Imazio M, Lazaros G, Brucato A, Gaita F
Nature reviews. Cardiology 2016; (13(2)):99-105 doi:10.1038/nrcardio.2015.115.
PMID: 26259934 - 5
Acute recurrent pericarditis: from pathophysiology towards new treatment strategy.
Cacoub P, Marques C
Heart (British Cardiac Society) 2020; (106(14)):1046-1051 doi:10.1136/heartjnl-2019-316481.
PMID: 32238419 - 6
Recurrent pericarditis: an update on diagnosis and management.
Vecchiè A, Dell M, Mbualungu J, et al.
Panminerva medica 2021; (63(3)):261-269 doi:10.23736/S0031-0808.21.04210-5.
PMID: 33618510 - 7
Current Drug Treatment for Acute and Recurrent Pericarditis.
Bonaventura A, Santagata D, Vecchié A, Abbate A
Drugs 2025; (85(5)):643-658 doi:10.1007/s40265-025-02169-x.
PMID: 40119189 - 8
Recurrent Pericarditis: Modern Approach in 2016.
Imazio M, Adler Y, Charron P
Current cardiology reports 2016; (18(6)):50 doi:10.1007/s11886-016-0727-8.
PMID: 27108360 - 9
Recurrent pericarditis.
Imazio M, Battaglia A, Gaido L, Gaita F
La Revue de medecine interne 2017; (38(5)):307-311 doi:10.1016/j.revmed.2016.12.006.
PMID: 28185680 - 10
Recurrent pericarditis in children and adolescents: a multicentre cohort study.
Imazio M, Brucato A, Pluymaekers N, et al.
Journal of cardiovascular medicine (Hagerstown, Md.) 2016; (17(9)):707-12 doi:10.2459/JCM.0000000000000300.
PMID: 27467459 - 11
Corticosteroids for Acute and Recurrent Idiopathic Pericarditis: Unexpected Evidences.
Perrone A, Castrovilli A, Piazzolla G, et al.
Cardiology research and practice 2019; (2019()):1348364 doi:10.1155/2019/1348364.
PMID: 31929897 - 12
Pericarditis and Autoinflammation: A Clinical and Genetic Analysis of Patients With Idiopathic Recurrent Pericarditis and Monogenic Autoinflammatory Diseases at a National Referral Center.
Peet CJ, Rowczenio D, Omoyinmi E, et al.
Journal of the American Heart Association 2022; (11(11)):e024931 doi:10.1161/JAHA.121.024931.
PMID: 35658515 - 13
Anakinra as rescue therapy for steroid-dependent idiopathic recurrent pericarditis in children: case report and literature review.
Rodriguez-Gonzalez M, Ruiz-Gonzalez E, Castellano-Martinez A
Cardiology in the young 2019; (29(2)):241-243 doi:10.1017/S1047951118002020.
PMID: 30511600 - 14
New Developments in the Management of Recurrent Pericarditis.
Imazio M, Mardigyan V, Andreis A, et al.
The Canadian journal of cardiology 2023; (39(8)):1103-1110 doi:10.1016/j.cjca.2023.04.008.
PMID: 37075863 - 15
The Impact of Physical Activity on Pericarditis.
Grant JK, Shah NP
Current cardiology reports 2021; (23(10)):150 doi:10.1007/s11886-021-01578-0.
PMID: 34448954 - 16
Rilonacept for Recurrent Postcardiac Injury Syndrome Pericarditis in a Young Hockey Player: When to Return to Exercise.
Massad F, Rosenzveig A, Reiss S, et al.
JACC. Case reports 2025; (30(31)):105326 doi:10.1016/j.jaccas.2025.105326.
PMID: 41072967
This page is for informational purposes only and does not constitute medical advice. Treatment doses, tapering, monitoring, and activity limits for recurrent pericarditis must be individualized with your clinician.